Synaptogenix Announces $5.0 Million Financing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 11 2024
0mins
Source: Newsfilter
Financing Announcement: Synaptogenix, Inc. has secured $5 million in financing through the sale of 5,000 shares of Series C convertible preferred stock to existing investors, with the offering expected to close on September 12, 2024.
Company Background: The company focuses on developing therapeutics for neurodegenerative disorders, notably its lead candidate Bryostatin-1, which has shown promise in treating Alzheimer's disease and received Orphan Drug Designation for Fragile X syndrome.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
